Interleukin-1 and tumor necrosis factor α blockade treatment of experimental polymyositis in mice

Arthritis and Rheumatism

Volumn 64, Issue 8, 2012, Pages 2655-2662

  Sugihara, Takahiko ^a,b   Okiyama, Naoko ^a,b   Watanabe, Naoto ^a   Miyasaka, Nobuyuki ^a   Kohsaka, Hitoshi ^a,b  

^a TOKYO MEDICAL AND DENTAL UNIVERSITY   (Japan)

^b RIKEN YOKOHAMA INSTITUTE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

CD11B ANTIGEN; CD68 ANTIGEN; ETANERCEPT; INTERLEUKIN 1; INTERLEUKIN 1 ANTIBODY; INTERLEUKIN 1ALPHA; INTERLEUKIN 1BETA; MESSENGER RNA; PROTEIN C; RECOMBINANT INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR ALPHA ANTIBODY;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DISEASE SEVERITY; DRUG TARGETING; FEMALE; GENE EXPRESSION; HISTOPATHOLOGY; IMMUNIZATION; IMMUNOHISTOCHEMISTRY; MACROPHAGE; MOUSE; MUSCLE TISSUE; MYOSITIS; NONHUMAN; POLYMYOSITIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION;

ANIMALS; ANTIBODIES, MONOCLONAL; DISEASE MODELS, ANIMAL; FEMALE; IMMUNOGLOBULIN G; INTERLEUKIN 1 RECEPTOR ANTAGONIST PROTEIN; INTERLEUKIN-1; MICE; MICE, INBRED C57BL; MICE, INBRED STRAINS; MUSCLE, SKELETAL; POLYMYOSITIS; RECEPTORS, INTERLEUKIN-1; RECEPTORS, TUMOR NECROSIS FACTOR; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84864479950     PISSN: 00043591     EISSN: 15290131     Source Type: Journal    
DOI: 10.1002/art.34465     Document Type: Article

References (49)

1. Dalakas MC, Hohlfeld R,. Polymyositis and dermatomyositis. Lancet 2003; 362: 971-82.
2. Arahata K, Engel AG,. Monoclonal antibody analysis of mononuclear cells in myopathies. I: quantitation of subsets according to diagnosis and sites of accumulation and demonstration and counts of muscle fibers invaded by T cells. Ann Neurol 1984; 16: 193-208.
3. Engel AG, Arahata K,. Monoclonal antibody analysis of mononuclear cells in myopathies. II: phenotypes of autoinvasive cells in polymyositis and inclusion body myositis. Ann Neurol 1984; 16: 209-15.
4. Goebels N, Michaelis D, Engelhardt M, Huber S, Bender A, Pongratz D, et al. Differential expression of perforin in muscle-infiltrating T cells in polymyositis and dermatomyositis. J Clin Invest 1996; 97: 2905-10.
5. Emslie-Smith AM, Arahata K, Engel AG,. Major histocompatibility complex class I antigen expression, immunolocalization of interferon subtypes, and T cell-mediated cytotoxicity in myopathies. Hum Pathol 1989; 20: 224-31.
6. + T cells. J Exp Med 1995; 181: 1863-8.
7. Nishio J, Suzuki M, Miyasaka N, Kohsaka H,. Clonal biases of peripheral CD8 T cell repertoire directly reflect local inflammation in polymyositis. J Immunol 2001; 167: 4051-8.
8. Williams RO, Feldmann M, Maini RN,. Anti-tumor necrosis factor ameliorates joint disease in murine collagen-induced arthritis. Proc Natl Acad Sci U S A 1992; 89: 9784-8.
9. Taniguchi K, Kohsaka H, Inoue N, Terada Y, Ito H, Hirokawa K, et al. Induction of the p16INK4a senescence gene as a new therapeutic strategy for the treatment of rheumatoid arthritis. Nat Med 1999; 7: 760-7.
10. Sekine C, Sugihara T, Miyake S, Hirai H, Yoshida M, Miyasaka N, et al. Successful treatment of animal models of rheumatoid arthritis with small-molecule cyclin-dependent kinase inhibitors. J Immunol 2008; 180: 1954-61.
11. Takagi N, Mihara M, Moriya Y, Nishimoto N, Yoshizaki K, Kishimoto T, et al. Blockage of interleukin-6 receptor ameliorates joint disease in murine collagen-induced arthritis. Arthritis Rheum 1998; 41: 2117-21.
12. Lipsky PE, van der Heijde DM, St Clair EW, Furst DE, Breedveld FC, Kalden JR, et al, for the Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group. Infliximab and methotrexate in the treatment of rheumatoid arthritis. N Engl J Med 2000; 343: 1594-602.
13. Klareskog L, van der Heijde D, de Jager JP, Gough A, Kalden J, Malaise M, et al. Therapeutic effect of the combination of etanercept and methotrexate compared with each treatment alone in patients with rheumatoid arthritis: double-blind randomised controlled trial. Lancet 2004; 363: 675-81.
14. Jiang Y, Genant HK, Watt I, Cobby M, Bresnihan B, Aitchison R, et al. A multicenter, double-blind, dose-ranging, randomized, placebo-controlled study of recombinant human interleukin-1 receptor antagonist in patients with rheumatoid arthritis: radiologic progression and correlation of Genant and Larsen scores. Arthritis Rheum 2000; 43: 1001-9.
15. Smolen JS, Beaulieu A, Rubbert-Roth A, Ramos-Remus C, Rovensky J, Alecock E, et al, for the OPTION Investigators. Effect of interleukin-6 receptor inhibition with tocilizumab in patients with rheumatoid arthritis (OPTION study): a double-blind, placebo-controlled, randomised trial. Lancet 2008; 371: 987-97.
16. Sugihara T, Sekine C, Nakae T, Kohyama K, Harigai M, Iwakura Y, et al. A new murine model to define the critical pathologic and therapeutic mediators of polymyositis. Arthritis Rheum 2007; 56: 1304-14.
17. Matsubara S, Shima T, Takamori M,. Experimental allergic myositis in SJL/J mice immunized with rabbit myosin B fraction: immunohistochemical analysis and transfer. Acta Neuropathol 1993; 85: 138-44.
18. Sugihara T, Okiyama N, Suzuki M, Kohyama K, Matsumoto Y, Miyasaka N, et al. Definitive engagement of cytotoxic CD8 T cells in C-protein induced myositis, a murine model of polymyositis. Arthritis Rheum 2010; 62: 3088-92.
19. Efthimiou P, Schwartzman S, Kagen LJ,. Possible role for tumour necrosis factor inhibitors in the treatment of resistant dermatomyositis and polymyositis: a retrospective study of eight patients. Ann Rheum Dis 2006; 65: 1233-6.
20. Dastmalchi M, Grundtman C, Alexanderson H, Mavragani CP, Einarsdottir H, Helmers SB, et al. A high incidence of disease flares in an open pilot study of infliximab in patients with refractory inflammatory myopathies. Ann Rheum Dis 2008; 67: 1670-7.
21. The Muscle Study Group. A randomized, pilot trial of etanercept in dermatomyositis. Ann Neurol 2011; 70: 427-36.
22. Okiyama N, Sugihara T, Iwakura Y, Yokozeki H, Miyasaka N, Hitoshi Kohsaka,. Therapeutic effects of interleukin-6 blockade in a murine model of polymyositis that does not require interleukin-17A. Arthritis Rheum 2009; 60: 2505-12.
23. Lundberg I, Ulfgren AK, Nyberg P, Andersson U, Klareskog L,. Cytokine production in muscle tissue of patients with idiopathic inflammatory myopathies. Arthritis Rheum 1997; 40: 865-74.
24. Kuru S, Inukai A, Liang Y, Doyu M, Takano A, Sobue G,. Tumor necrosis factor-α expression in muscles of polymyositis and dermatomyositis. Acta Neuropathol 2000; 99: 585-8.
25. Kojima T, Tanuma N, Aikawa Y, Shin T, Sasaki A, Matsumoto Y,. Myosin-induced autoimmune polymyositis in the rat. J Neurol Sci 1997; 151: 141-8.
26. Kohyama K, Matsumoto Y,. C protein in the skeletal muscle induces severe autoimmune polymyositis in Lewis rats. J Neuroimmunol 1999; 98: 130-5.
27. Lundberg I, Kratz AK, Alexanderson H, Patarroyo M,. Decreased expression of interleukin-1α, interleukin-1β, and cell adhesion molecules in muscle tissue following corticosteroid treatment in patients with polymyositis and dermatomyositis. Arthritis Rheum 2000; 43: 336-48.
28. Grundtman C, Salomonsson S, Dorph C, Bruton J, Andersson U, Lundberg IE,. Immunolocalization of interleukin-1 receptors in the sarcolemma and nuclei of skeletal muscle in patients with idiopathic inflammatory myopathies. Arthritis Rheum 2007; 56: 674-87.
29. Nagaraju K, Raben N, Merritt G, Loeffler L, Kirk K, Plotz P,. A variety of cytokines and immunologically relevant surface molecules are expressed by normal human skeletal muscle cells under proinflammatory stimuli. Clin Exp Immunol 1998; 113: 407-14.
30. Chevrel G, Granet C, Miossec P,. Contribution of tumour necrosis factor α and interleukin (IL) 1β to IL6 production, NF-κB nuclear translocation, and class I MHC expression in muscle cells: in vitro regulation with specific cytokine inhibitors. Ann Rheum Dis 2005; 64: 1257-62.
31. Guttridge DC, Mayo MW, Madrid LV, Wang CY, Baldwin AS Jr,. NF-κB-induced loss of MyoD messenger RNA: possible role in muscle decay and cachexia. Science 2000; 289: 2363-6.
32. Nakae S, Asano M, Horai R, Sakaguchi N, Iwakura Y,. IL-1 enhances T cell-dependent antibody production through induction of CD40 ligand and OX40 on T cells. J Immunol 2001; 167: 90-7.
33. Saijo S, Asano M, Horai R, Yamamoto H, Iwakura Y,. Suppression of autoimmune arthritis in interleukin-1-deficient mice in which T cell activation is impaired due to low levels of CD40 ligand and OX40 expression on T cells. Arthritis Rheum 2002; 46: 533-44.
34. Eriksson U, Kurrer MO, Sonderegger I, Iezzi G, Tafuri A, Hunziker L, et al. Activation of dendritic cells through the interleukin 1 receptor 1 is critical for the induction of autoimmune myocarditis. J Exp Med 2003; 197: 323-31.
35. Miossec P, Korn T, Kuchroo VK,. Interleukin-17 and type 17 helper T cells. N Engl J Med 2009; 361: 888-98.
36. Sutton C, Brereton C, Keogh B, Mills K, Lavelle EC,. A crucial role for interleukin (IL)-1 in the induction of IL-17-producing T cells that mediate autoimmune encephalomyelitis. J Exp Med 2006; 203: 1685-91.
37. Nakae S, Saijo S, Horai R, Sudo K, Mori S, Iwakura Y,. IL-17 production from activated T cells is required for the spontaneous development of destructive arthritis in mice deficient in IL-1 receptor antagonist. Proc Natl Acad Sci U S A 2003; 100: 5986-90.
38. Arnold L, Henry A, Poron F, Baba-Amer Y, van Rooijen N, Plonquet A, et al. Inflammatory monocytes recruited after skeletal muscle injury switch into antiinflammatory macrophages to support myogenesis. J Exp Med 2007; 204: 1057-69.
39. The Lenercept Multiple Sclerosis Study Group and The University of British Columbia MS/MRI Analysis Group. TNF neutralization in MS: results of a randomized, placebo-controlled multicenter study. Neurology 1999; 53: 457-65.
40. Liu J, Marino MW, Wong G, Grail D, Dunn A, Bettadapura J, et al. TNF is a potent anti-inflammatory cytokine in autoimmune-mediated demyelination. Nat Med 1998; 4: 78-83.
41. Soforo E, Baumgartner M, Francis L, Allam F, Phillips PE, Perl A,. Induction of systemic lupus erythematosus with tumor necrosis factor blockers. J Rheumatol 2010; 37: 204-5.
42. Kontoyiannis D, Kollias G,. Accelerated autoimmunity and lupus nephritis in NZB mice with an engineered heterozygous deficiency in tumor necrosis factor. Eur J Immunol 2000; 30: 2038-47.
43. Jacob CO, McDevitt HO,. Tumour necrosis factor-α in murine autoimmune 'lupus' nephritis. Nature 1988; 331: 356-8.
44. Campbell IK, O'Donnell K, Lawlor KE, Wicks IP,. Severe inflammatory arthritis and lymphadenopathy in the absence of TNF. J Clin Invest 2001; 107: 1519-27.
45. Nakae S, Nambu A, Sudo K, Iwakura Y,. Suppression of immune induction of collagen-induced arthritis in IL-17-deficient mice. J Immunol 2003; 171: 6173-7.
46. Hall HA, Zimmermann B,. Evolution of dermatomyositis during therapy with a tumor necrosis factor α inhibitor. Arthritis Rheum 2006; 55: 982-4.
47. Ishikawa Y, Yukawa N, Ohmura K, Hosono Y, Imura Y, Kawabata D, et al. Etanercept-induced anti-Jo-1-antibody-positive polymyositis in a patient with rheumatoid arthritis: a case report and review of the literature. Clin Rheumatol 2010; 29: 563-6.
48. Kohsaka H,. Current insights in polymyositis and dermatomyositis. Clin Exp Neuroimmunol 2010; 1: 22-32.
49. Sontheimer RD,. Cutaneous features of classic dermatomyositis and amyopathic dermatomyositis. Curr Opin Rheumatol 1999; 11: 475-82.